TCF3 and acute lymphoblastic leukemia: We observed that some B-ALL subtypes namely 697 (TCF3::PBX1), NALM6 (DUX4-rearranged), SUPB15 (BCR::ABL1), HAL01 (TCF3::HLF) and the ETV6::RUNX1 positive REH’s had significantly reduced viability after RSL3 and volasertib treatment (Fig. 4B).